Abstract Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the US Food and Drug
Administration for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small …

ROS1 is one of 58 receptor tyrosine kinases, and one of two orphan receptor tyrosine
kinases where its ligand is unknown. ROS1 is evolutionarily related to ALK. ROS1 …

Oncogenic c-ros oncogene1 (ROS1) fusion kinases have been identified in a variety of
human cancers and are attractive targets for cancer therapy. The MET/ALK/ROS1 inhibitor …

Background To determine the prevalence and clinicopathological features of ROS1 fusions
in Chinese patients with non-small-cell lung cancer (NSCLC). Methods Formalin-fixed and …

Background The study was conducted to investigate the clinicopathological features and
prevalence of ROS1 gene fusion in Chinese patients with non‐small cell lung cancer …

An anaplastic lymphoma kinase (ALK) translocation giving rise to activated ALK tyrosine
kinase is present in approximately 5% of non–small-cell lung cancers (NSCLCs). Crizotinib …

DISCUSSION In NSCLC, some molecular aberrations, including EGFR mutation, and ALK,
ROS1, and RET fusions, are shown to be associated with specific clinical characteristics and …

Lung cancer is the leading cause of cancer mortality in the United States and worldwide, 1, 2
and the prognosis remains poor with an estimated 5-year overall survival (OS) rate of 15%. 2 …

到目前为止, 在NSCLC 中发现了17 种较少见的ROS1 融合基因: GOPC⁃ ROS1, LIMAI⁃
ROS1, MSN⁃ ROS1, FIG⁃ ROS1, CCDC6⁃ ROS1, KDELR2⁃ ROS1, LRIG3⁃ ROS1 …

Globally, lung cancer remains the most common cause of cancer-related death. In recent
years, it has become clear that development of rational molecular targeted therapies is …